- Ongoing, recruitingTherapeutic exploratory (Phase II)
A Phase 2, multicenter, open-label study of lifileucel (tumor-infiltrating lymphocytes [TIL]) in participants with previously treated advanced melanoma
This study is looking at a new treatment called lifileucel for people with advanced melanoma that has already been treated. It's an early-stage study to see how well the treatment works and if it's safe. It uses your own immune cells to fight the cancer.
For: Previously treated advanced melanomaFrance · Italy · Germany - Ongoing, recruitingTherapeutic exploratory (Phase II)
A Phase 2, Multicenter Study of Autologous Tumor Infiltrating Lymphocytes (LN-144/LN-145/LN-145-S1) in Patients with Solid Tumors
This study looks at a new treatment for solid tumours, which are common types of cancer. It uses a patient's own immune cells, called TILs, to fight the cancer. Researchers want to see how well these cells work at shrinking tumours and keeping the cancer away.
For: NeoplasmSpain · Germany · Greece - Active not recruitingPHASE2
A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced Melanoma
This study is testing a new treatment called lifileucel for advanced melanoma, a type of skin cancer. It's for adults whose cancer has continued to grow despite previous treatments. The aim is to see if lifileucel can help control the cancer.
For: Melanoma (Skin Cancer) · Unresectable Melanoma · Metastatic MelanomaUnited States · Australia · Canada - RecruitingPHASE3
SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma
This study compares a new treatment called IMA203 with standard care for advanced skin melanoma that has already been treated. Its main goal is to see if IMA203 is more effective and safe for patients who have limited treatment options.
For: Melanoma, Cutaneous MalignantUnited States · Canada · France